DEF 14A: CERo Therapeutics Seeks Stockholder Approval for Reverse Stock Split, Share Issuance, and Incentive Plan Increase

CERo Therapeutics is asking stockholders to approve a reverse stock split, the issuance of shares related to convertible preferred stock and warrants, and an increase in the company's equity incentive plan.

Summary

• CERo Therapeutics Holdings, Inc. is holding a special meeting of stockholders on November 4, 2024, to vote on four proposals.
• The first proposal seeks approval for an amendment to the company's Certificate of Incorporation to enact a reverse stock split at a ratio between 1-for-25 and 1-for-150, with the exact ratio determined by the Board of Directors.
• The second proposal concerns the approval of the issuance of shares of Common Stock upon the conversion of Series C convertible preferred stock and the exercise of warrants issued in a private placement in September 2024, in accordance with Nasdaq Listing Rule 5635.
• The third proposal involves increasing the number of shares available under the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan by 20,845,391 shares.
• The fourth proposal requests approval for adjourning the Special Meeting, if necessary, to allow for further solicitation of proxies if there are insufficient votes for the first three proposals.
• The Board of Directors recommends voting FOR all four proposals.
• The record date for determining stockholders eligible to vote is October 2, 2024.
• The company's Common Stock closed at $0.088 per share on Nasdaq as of the Record Date.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is taking steps to address its financial situation and Nasdaq compliance, the need for a reverse stock split and potential further capital raises suggests underlying challenges. The sentiment is cautiously optimistic, but with significant risks.

Positives

• The reverse stock split aims to increase the stock price to meet Nasdaq listing requirements and attract a broader range of investors.
• Approval of the share issuance proposal would allow the company to proceed with planned conversions and warrant exercises, potentially providing additional capital.
• Increasing the equity incentive plan share reserve would enable the company to attract and retain key employees through equity compensation.
• The company believes hosting a virtual meeting will minimize travel expenses and enable greater stockholder attendance and participation.

Negatives

• Failure to approve the reverse stock split could lead to delisting from Nasdaq.
• The reverse stock split may not result in a sustained increase in the stock price.
• The issuance of additional shares could dilute existing stockholders' ownership.
• The company has received letters from Nasdaq regarding non-compliance with listing requirements.

Risks

• The reverse stock split may not increase the per share price of the Common Stock.
• The market price of the Common Stock may decline after the Reverse Stock Split.
• The Reverse Stock Split would result in an increased proportion of unissued authorized shares to issued shares, which could have possible anti-takeover effects.
• The company may be unable to obtain alternative financing if the Nasdaq Share Issuance Proposal is not approved.
• If the company is unable to successfully raise sufficient additional capital, it will not have sufficient cash to fund its planned business operations and or may not be able to continue as a going concern.

Future Outlook

The company is exploring various sources of financing, including potential future sales of Common Stock or other securities, to fund its planned business operations.

Management Comments

• Chris Ehrlich, Interim Chairman and Chief Executive Officer, encourages stockholders to vote as soon as possible to ensure their shares are represented.

Industry Context

The document does not explicitly discuss broader industry trends, but the reverse stock split is a common strategy for companies facing delisting from exchanges like Nasdaq.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• Reverse stock splits are a common tactic for companies facing delisting, but their success varies widely depending on company-specific factors and market conditions.
• The terms of the Series C Preferred Stock and Warrants, including the anti-dilution provisions and conversion/exercise price adjustments, are typical for private placements of this nature.

Related Party Transactions

• On December 13, 2022, PBAX issued an unsecured promissory note in the principal amount of $1,500,000 (the Promissory Note) to the Sponsor, pursuant to which the Sponsor agreed to loan to the PBAX up to $1,500,000.
• On December 8, 2023, the Promissory Note was amended to increase the total principal amount to $1,600,000.
• At the closing, an aggregate of approximately $1.55 million that had been borrowed under the Promissory Note was extinguished and converted into an aggregate of 1,380 shares of Series A convertible preferred stock, par value $0.0001 per share (the Series A Preferred Stock).
• Commencing on October 6, 2021, PBAX paid an amount equal to $20,000 per month to the Sponsor or its affiliate or designee for office space, administrative and shared personnel support services provided to PBAX.
• The Company engaged Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC (CCM), an affiliate of PBAX, the Sponsor and/or certain of its directors and officers, to provide consulting and advisory services in connection with its initial public offering, for which it was entitled to a fee in an amount equal to $465,000, which was paid to CCM upon the closing of its initial public offering, and $1,162,500, which would have been paid to CCM upon the closing.
• In connection with the closing, PBAX entered into a fee modification agreement with CCM pursuant to which CCM forfeited such fees and the Company issued an aggregate of 1,200,000 shares of Common Stock, with 1,000,000 of such shares being subject to forfeiture unless the Company conducts a capital-raising transaction within nine months of the closing, pursuant to which the Company shall issue and sell securities in an aggregate amount of at least $25.0 million, affiliates of CCM have and manage investment vehicles with a passive investment in the Sponsor.
• On March 3, 2020, Legacy CERo entered into a collaboration and option agreement (Collaboration Agreement) with a collaborative partner that was an investor of Legacy CERo, pursuant to which each party was granted a royalty-free, nonexclusive, worldwide license to share the other partys technologies to create bi-functional T-cells.
• Under the Collaboration Agreement, the collaborative partner paid the Company $182,577 and $0 for the years ended December 31, 2022 and 2023.
• In February 2024, we issued and sold an aggregate of 10,039 shares of Series A Preferred Stock, 612,746 Series A Warrants (as defined below) and 2,500 Preferred Warrants (as defined below), at a price of $1,000 per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $8.0 million, plus additional cash proceeds of up to $2.0 million if the Preferred Warrants are exercised.

Stakeholder Impact

• Shareholders face potential dilution and the risk of delisting if the proposals are not approved.
• Employees may benefit from the increased equity incentive plan, but also face uncertainty related to the company's financial stability.
• The company's ability to fund its operations and advance its drug candidates depends on the outcome of the vote and its ability to secure additional financing.

Next Steps

• Stockholders will vote on the proposals at the Special Meeting on November 4, 2024.
• The Board of Directors will determine whether to implement the reverse stock split and at what ratio, if approved by stockholders.
• The company will file a Certificate of Amendment with the Secretary of State of Delaware if the reverse stock split is approved and implemented.
• The company will continue to explore financing options to fund its operations.

Key Dates

Keywords

reverse stock split, proxy statement, share issuance, equity incentive plan, Nasdaq, stockholders, CERo Therapeutics, preferred stock, warrants, listing requirements